Ultra early molecular biologic diagnosis of malignant and neurodegenerative diseases by the immunospecific profiles of the proteins markers of the surface of the mobilized autologous hematopoietic stem cells.

The comparative study of the protein markers of the membrane surface of the autologous hematopoietic stem cells (СD34+ СD45+) was performed to detect the patterns of the proteomic profiles, if any. The study included five groups. The subpopulations of the hematopoietic stem cells were studied in 569 samples of the mobilized peripheral blood mononuclear cells from adult cancer cases (group 1), 557 samples from children cancer cases (group 2), 66 samples from amyotrophic lateral sclerosis cases (group 3), 5 samples from other neurodegenerative diseases cases (supplementary group 4) and 61 samples isolated from healthy donors (control group 5).

Azoximer Bromide: Mystery, Serendipity, and Promise.

Azoximer bromide (AZB) was identified as an immunomodulator, and was initially developed and currently successfully indicated as one of several natural polyelectrolytes, a vaccine adjuvant, and an effective agent for the treatment of infectious and inflammatory diseases of viral, bacterial, and fungal origin. AZB has the potential to increase an individual's resistance to local and general infection and is indicated for the treatment of viral infections, and has also demonstrated clinical efficacy in the treatment of a variety of secondary immunodeficiencies. However, AZB may offer long-term promise beyond use against infection.

Is the ALS a motor neuron disease or a hematopoietic stem cell disease?

Introduction: Amyotrophic lateral sclerosis (ALS) is also known as motor neuron disease (MND) or Lou Gehrig's disease. It is a fatal neurodegenerative disease the cause of which is not clear. The effective therapy is absent.